

Cyclohepta[*b*][1,4]benzothiazines and Their Diazine Analogues. 2. Formation and Properties of Cyclohepta[*b*]quinoxalines^{1,2)}

Kimio SHINDO,* Sumio ISHIKAWA, and Tetsuo NOZOE*,†

Department of Chemistry, Faculty of Science, Josai University, 1-1 Keyakidai, Sakado-shi, Saitama-ken 350-02


†Tokyo Research Laboratories, Kao Corporation, 2-1-3 Bunka, Sumida-ku, Tokyo 131

(Received October 17, 1988)


2-Chloro- or 2-methoxytropone reacts with *o*-phenylenediamine to give 2-(*o*-aminoanilino)tropone, which upon heating provides 6*H*-cyclohepta[*b*]quinoxaline (**10a**). Upon acidification, **10a** reversibly gives a green cation, **9a**. **10a** is easily converted, especially under basic conditions, into the oxidative dimer **16a**, which reproduces **9a** by reduction with Zn in acetic acid. The isopropyl derivatives of these compounds are prepared by the same method from 5-isopropyl-2-methoxytropone. The 5-methyl (**21a**) and 5,11-dimethyl derivatives **23** are made by the reaction of 2-chloro- or 2-methoxytropone with *N*-methyl- and *N,N'*-dimethyl-*o*-phenylenediamines. However, the methylation of **21a** with methyl fluorosulfate affords 5,11-dihydro-8,11-dimethyl-6*H*-cyclohepta[*b*]quinoxaline-5,6-sultone. H₂O₂ oxidation of **10a** mainly gives **16a** in addition to a small quantity of 6*H*-cyclohepta[*b*]quinoxalin-6-one. Compound **21a** is stable under basic conditions, but **23** rearranges under alkaline conditions to give, among other unidentified products, *N*-methyl-*N*-(*o*-(methylamino)phenyl)benzamide and 5,10-dihydro-5,10-dimethyl-2-phenazinecarbaldehyde. Reactions of title compounds with alkali and hydrogen peroxide are compared with those of *O*- and *S*-analogues.

One of the authors (T.N.) and his co-workers reported about thirty years ago that reactions of 5-nitroso- and 5-arylazotropolone (**1a,b**) with *o*-phenylenediamine (**2a**) gave quinoxaline derivatives (**3a,b**), which were considered to have quinonoid structures.³⁾ They subsequently found⁴⁾ that the reactions of 2-chloro- and 2-methoxytropone (**4a,b**) with **2a** afforded pale-violet crystals **A**, which, on catalytic reduction, produced **6a** and **7a** almost quantitatively.^{4,5)} They presumed that **A** was 5*H*-cyclohepta[*b*]quinoxaline


(**5a**), which they named "benzo[*b*]tropazine."⁴⁾ However, they could not determine the position of the H-atom of **5a,b**, because NMR spectroscopy was not available at that time. Furthermore, they found that the reaction of 3-carboxytropolone (**4c**) with *o*-phenylenediamine (**2a**) and its methyl homologue (**2b**) produced **A** and its methyl derivative **B**, respectively. The former gave **6a** and **7a**, and the latter afforded their respective methyl derivatives (**6b** and **7b**) upon catalytic reduction. They attempted to purify the colored




1a: X=O
b: X=NAr




3a: X=O
b: X=NAr




2	R ¹	R ²
a	H	H
b	Me	H
c	Me	Me




4	X	R
a	Cl	H
b	OMe	H
c	OH	3-COOH
d	OMe	5-i-Pr




5a: R=H
b: R=Me




6a: R=H
b: R=Me




7a: R=H
b: R=Me



8



9a: R=H
c: R=Me




10a: R=H
c: R=Me


product **A** by using an alumina column chromatography and obtained colorless crystals **C** that were sparingly soluble in the usual organic solvents. They then considered that **C** was pure "benzo[*b*]tropazine" (**5a**).

In 1971, Fukunaga reported⁵⁾ that the reaction of ethoxytropylium tetrafluoroborate (**8**) with *o*-phenylenediamine (**2a**) and its dimethyl derivative (**2c**) gave greenish-black crystals **9a,c**, which upon basification produced neutral species **10a,c** that reverted to **9a,c** quantitatively upon acidification.⁵⁾ He believed that the structure of **10** was the quinoxaline form, and **9** existed as a resonance-stabilized (aromatic) peripheral 16 π electron system on the evidence of detailed NMR studies. He also recognized that **10** was easily dimerized oxidatively during alumina chromatography and suggested that the colorless product **C** obtained by Nozoe⁴⁾ was an oxidative dimer derived from **10a**; however, its structure was not studied.⁵⁾

Recently, we reported in detail on cyclohepta[*b*]-[1,4]benzoxazine (**11**)⁶⁾ and its *S*-analogue (**12**)⁷⁾ we also reexamined previous studies on "benzo[*b*]tropazine"⁴⁾ because before-mentioned Fukunaga's research⁵⁾ has remained unpublished. In this report we wish to describe the detailed study on reactions of the reactive trononoids **4a,b,d** with *o*-phenylenediamine (**2a**) and its derivatives (**20a,b**).



11



12

Results and Discussion

We first observed the reaction of **4a** with **2a** in EtOH by using time-dependent HPLC by the same method as in the case of the *S*-analogues.⁸⁾ It was found that




Fig. 1. Time-dependent HPLC chromatograms of the reaction mixture of **4a** with **2a** in EtOH at 80°C.





Fig. 2. Time-dependent HPLC chromatograms of the reaction mixture of **4b** with **2a** in EtOH at 80°C.

2-(*o*-aminoanilino)tropone (**13a**) formed at an early stage of the reaction was gradually transformed into **10a** and highly polar **9a**. Finally, **13a** and **10a** almost disappeared; in addition to the main peak of polar **9a**, broad peaks with retention time (RT) 32 min (**D**), 44 min (**E**), and 57 min (**F**) appeared (see Fig. 1).

A similar reaction of **4b** with **2a** under nitrogen looked very simple chromatographically, giving **13a** and **10a** in good yields without the formation of **9a** and **D**, **E** (Fig. 2).

Compound **13a**, obtained as yellow needles, mp 183 °C, by the reaction of **4b** with **2a** in a sealed tube at 80 °C, was identified as 2-(*o*-aminoanilino)tropone on the basis of its IR, UV, NMR, and mass spectra, as well as elemental analysis; for assignments of the spectral signals, see the Experimental section. Upon further heating at 120 °C in a sealed tube, **13a** gave the dehydrated product as pale-yellow needles mp 69 °C, *m/z* 194 (M^+). This product was confirmed spectroscopically to exist in the quinoxaline form **10a**;⁵⁾ a methylene proton signal appeared at δ 3.59 (NMR), NH absorption was not seen in the IR and NMR spectra, and there was no absorption in the visible region.

Although the existence of the tautomeric form **5a** ("benzo[*b*]tropazine") could not be detected spectroscopically, upon treatment of **10a** with MeOH-*d*₄ and a small amount of triethylamine at 40 °C, the H₂-6 signal gradually disappeared, presumably giving rise to the formation of deuterio compound **14** via "enamine" form **5a**.



13a: R=H
b: R=i-Pr

14

15

When **10a** (RT, 15 min) was heated in acetic anhydride containing a small amount of 1,4-diazabicyclo-[2.2.2]octane (Dabco) under nitrogen, we could observe (in the HPLC diagram) a new peak (RT, 12 min), having UV absorption maxima at 225, 253, and 385 nm and m/z 236 (M^+) corresponding to the *N*-acetyl derivative **15**; the exact structure of **15**, however, could not be confirmed because of its instability.

On acidification of both **13a** and **10a** were converted into a dark-green salt **9a**, which showed considerably long-wavelength absorption bands at 564, 616, 670, and 752 nm ($\log \epsilon$ 3.01, 2.91, 2.83, and 2.34), in addition to the three intense absorption bands (449, 464, and 491 nm) in the visible region (Fig. 3). The ^1H NMR spectrum of **9a** consisted of five 2H signals and a 1H signal (at δ 6.04, t, $J=9.5$ Hz, H-8), indicating a symmetric structure. Neutralizing of **9a** with alkali under nitrogen gave **10a** quantitatively, however, an oxidative dimeric product **16a** was gradually formed by the same treatment under aerobic conditions. Compound **16a** was also formed when **10a** was passed through an alumina column⁵⁾ or underwent heating in EtOH (in





Fig. 3. Electronic spectra of some cyclohepta[*b*]quinoxalines in MeOH.


this case, giving rise to two other products **E** and **F**, presumably oxidative oligomers of **10a** as well.) When **9a** and **10a** were (separately) treated with a base in open air, the former produced **16a** much faster than the latter, suggesting that **16a** was formed by the dimerization of radical **17**, that may be more readily derived from the diazinium form **9a** than from the 6*H*-cyclohepta[*b*]quinoxaline form **10a** (Scheme 1). Compound **16a** showed a UV spectrum similar to that of **10a**. The ^1H NMR spectrum of **16a** closely resembled that of **10a**, with the exception of the presence of a methine proton signal at δ 4.59 (instead of the H₂-6 signal of **10a** at δ 3.59), indicating also a symmetric structure. In the mass spectrum there are no fragment peaks between m/z 386 (M^+) and m/z 193 (M^+-193); we could therefore conclude that **16a** is the dehydro dimer (2H less in mass) of **10a**. Reduction of **16a** with Zn in AcOH was found to reproduce **9a** quantitatively. Heating of **16a** at 220 °C under vacuum gave **10a** and a reddish-brown substance, the latter being presumed a fulvalene derivative **19** on the basis of mass spectrometry [m/z 384 (M^+)] and UV spectrum; carbene **18** formed by disproportionation of radical **17** is suggested as the most likely intermediate to give **19** (Scheme 1). From the experimental evidence described so far, we now consider that colorless crystals **C**⁴⁾ must have been the dimer **16a**, as speculated by Fukunaga.⁵⁾ Further, the soluble, slightly colored substance used for the catalytic reduction⁴⁾ to give **6a** and **7a** was in fact pure **10a**, because our experimental results appear to be compatible with the Fukunaga's structures **9a** and **10a**⁵⁾ (except for their electronic structure).⁹⁾

To make sure the characteristics of cyclohepta[*b*]quinoxaline system, we also studied the isopropyl derivatives (**9b** and **10b**) prepared from 5-isopropyl-2-methoxytropone (**4d**) and **2a**, and we obtained a similar dimer **16b** reversibly from **9b**, as illustrated in Scheme 2.


We then tried to synthesize the *N*-methyl derivative **21a** (of **5a**), which can not take the tautomeric, qui-



Scheme 1.



Scheme 2.





nooxalo form, in order to compare its properties with those of the *O*- and *S*-analogues (**11**, **12**). Thus, *N*-methyl-5*H*-cyclohepta[*b*]quinoxaline (**21a**) was obtained as green needles having a low melting point (mp 68 °C), by the reaction of **4b** with *N*-methyl-*o*-phenylenediamine (**20a**). The structure of **21a** was established on the basis of the spectral data. It showed ¹H NMR signals at δ 2.67 (*N*-methyl), and at δ 4.47 (H-6) and 6.24 (H-4) due to two peri-protons; these were assigned on the basis of NOE experiment. It is worth noticing that the free *N*-methyl compound **21a** and its protonated cation **22a** have the same deep green color and are similar to **9a** in terms of the UV/VIS and ¹H NMR spectra, indicating that these compounds have a similar π -electron system.⁹⁾ We also prepared 8-isopropyl compound **21b** and its salt **22b** from methyl ether of γ -thujaplicin (5-isopropyltropolone).

N,N'-Dimethyl cation (**23**) was obtained as dark-greenish needles (chloride and BF₄⁻ salts) by heating **4a** or **4b** with *N,N'*-dimethyl-*o*-phenylenediamine (**20b**) at 120 °C in the presence of acid.²⁾ The long-wavelength absorptions at 578, 620, and 732 nm (log ϵ 3.07, 3.05, and 2.56) of **23** in MeOH are similar to those of **9a** and **22a** (Fig. 3). These bands disappear in alkali and exhibit only UV maxima of an unidentified conjugate base at 230, 250, 280, and 354 nm (they are restored upon acidification). The symmetrical structure

of **23** was confirmed by the NMR spectrum, which showed two methyl signals at δ 3.10 (well-resolved), three signals at δ 6.25, 6.57, and 7.24 (ratio 2 : 1 : 2) due to the seven-membered ring protons, and signals of A₂ B₂ type at δ 6.71 and 6.95 due to benzene ring protons.

We then attempted to obtain compound **23** by the treatment of **21a** with "magic methyl," which, however, resulted in the formation of green needles **24**, mp 127–128.5 °C, which had a molecular composition of C₁₅H₁₄N₂O₃S (gaining a methyl and an SO₃ groups) and showed characteristic IR absorptions (KBr) at 1340 and 1160 cm⁻¹ (–SO₂–). This product exhibited visible absorption at 616, 676, and 680 nm in MeOH, but in hexane the longest-wavelength absorption was at 434 nm; the absorption maxima in MeOH shifted to slightly longer wavelengths in the presence of acid. ¹H NMR signals in benzene-*d*₆ appeared at δ 1.63 and 3.29 due to two methyl protons and at δ 3.33 due to a methine proton in addition to seven olefinic proton signals, thus showing that **24** would preferably exist in the form of the intramolecular conjugate base form, 5,10-dihydro-8,11-dimethyl-6*H*-cyclohepta[*b*]quinoxaline-5,6-sultone (**24b**) in nonpolar aprotic solvent. However, the H-6, H-1, and Me-8 proton signals of **24** shifted downfield (1 ppm) in CD₃CN from those in benzene-*d*₆ and the spectral pattern became rather similar to that of **21a**, thus indicating that **24** is more likely to exist in another tautomeric form **24a** predominantly in a polar solvent and in a solid as well. On the other hand, in acidic methanol, the spectrum of **24b** closely resembled those of cyclohepta[*b*]quinoxalinium salts **9a** and **22**, suggesting the cationic form **24c** in acid. It should be noted that methylation with magic methyl takes place at the seven-membered ring of **21a** to give **24**; this differs from the case of methylation of *O*- and *S*-analogues (**11** and **12**) with magic methyl,⁸⁾ and also from the result of methylation of **21a** with methyl iodide.¹⁰⁾ Although the mechanism of this unusual reaction has not been clarified yet, one of the possible pathways is shown in Scheme 3.


A comparison is now made between the reactivities of 5*H*-cyclohepta[*b*]quinoxaline (**21** and **23**) and those of *O*- and *S*-analogues (**11** and **12**) and their respective




N-methylated cations (**25** and **26**). Facile ring opening by alkali and ring closure by acid is one of the characteristics of cyclohepta[*b*][1,4]benzoxazine **11** and its derivatives.⁶⁾ In particular, *N*-methyl derivative **25** is readily saponified to 2-(*N*-methyl-*o*-hydroxyanilino)-tropone **27** (even with water at room temperature), by the attack of hydroxide ion at C-5a. Although *S*-analogue **12** is stable to warm alkali, its *N*-methyl

cation **26** is saponified with cold alkali to give 2-[*o*-(methylamino)phenylthio]tropone **28** by an attack of the hydroxide ion at C-10a.⁸⁾

On the contrary, 5-methyl-5*H*-cyclohepta[*b*]quinoxaline **21a** is quite stable to warm alkali, whereas its *N,N'*-dimethyl cation **23a** give a colorless conjugate base by dilute alkali, but is restored to **23a** upon acidification. When a methanolic solution of **23a** containing 5 equiv of sodium hydroxide was allowed to stand overnight at room temperature, various products were formed (accompanied by autoxidation), from which a 6.5% yield of 5,10-dihydro-5,10-dimethyl-2-phenazincarbaldehyde (**30**)¹²⁾ and 11% of benzamide **29** were isolated. Possible pathways for the formation of these compounds are shown in Scheme 4. It is considered that in path (i), intermediate **a**₁, produced by the attack of a hydroxide anion at C-5 of **23**, gives **29** via norcaradiene **a**₂ as illustrated in the scheme, whereas in path (ii) intermediate **b**₁, produced by the attack of a hydroxide anion at C-7, aromatizes to **30** via **b**₂ by autoxidation. In concentrated methanolic alkali, however, **23** rearranges to benzamide **29** in 89% yield.






Scheme 5.

We then examined the reaction of 10a (or 9a) with hydrogen peroxide for a comparison with the behavior of the H_2O_2 to *O*- and *S*-analogues (11,⁶ 12^{7,8}). Our previous findings may be summarized as follows: (1) Treatment of *O*-analogue 11 with H_2O_2 in MeOH gave almost exclusively (96%) cyclohepta[*b*][1,4]benzoxazin-10(11*H*)-one (31) and 2–3% of the hydrolyzed product 32, along with a small proportion (<1%) of 1-formyl-10*H*-phenoxazine (33); for the reaction pathways, see Scheme 5. (2) The *S*-analogue 12 reacted⁸ with H_2O_2 in MeOH slightly more slowly than 11, producing many kinds of rearranged products, 10*H*-phenothiazine (34), its 1- and 3-formyl derivatives (35, 36).

On the other hand, oxidation of 10a with H_2O_2 in acetic acid gave mainly the dehydro dimer 16a mentioned above and a small quantity of E, F, and 6*H*-cyclohepta[*b*]quinoxalin-6-one (37).¹³ Compound 21a is stable under basic conditions and also to H_2O_2 in MeOH at room temperature; upon heating at 60 °C, however, it was gradually oxidized to a complex mixture of products. One of them was separated as a reddish oil, which was identified spectroscopically as 10-methyl-2(10*H*)-phenazinone (39).¹⁴ It was considered that 39 was formed by the oxidation of 5,10-dihydro-5-methylphenazine (38), derived from an oxidative rearrangement of 21a, because phenothiazines usually form quinone derivatives upon radical oxidation.¹⁵

It is interesting to note that cyclohepta[*b*][1,4]benzoxazine (11), its *S*-analogue 12, and *N*-analogues 10, 21 have considerable different chemical properties. These compounds can be regarded as π -excessive heteroaromatics¹⁶ fused with benzene and cycloheptatriene



rings. Therefore, the diversity of these reactivities could be explained in terms of the electronegativity and polarizability of the hetero atoms as well as the nature of the attaching reagents. However, detailed studies (including theoretical calculations) on the π -electron system of cyclohepta[*b*]quinoxalines and those *O*- and *S*-analogues in relation to their chemical properties are currently in progress, and the results will be reported in a future paper.¹⁷

Experimental

Melting points were determined with a Yanagimoto MP-

3S apparatus and are uncorrected. The IR spectra were taken on a Shimadzu IR-400 or IR-450, and the UV spectra were recorded with a Shimadzu UV-202 or a Hitachi 557 spectrometer. The NMR spectra were recorded with JEOL JNM-PS100 (100-MHz) and GX270 (270-MHz) spectrometers using TMS as the internal standard. The mass spectra were taken on Shimadzu LKB9000 and JEOL JMS-01SG mass spectrometers. The HPLC was carried out on Hitachi gel #3011 with MeOH-hexane (9:1) as the solvent. The UV spectra in acid and alkali were taken after adding a drop of 3 M HCl or 3 M NaOH (1 M=1 mol dm⁻³) to the sample solution. TLC analyses were carried out with Merck Kieselgel 60F-254 and Aluminium oxide F-254 plates.

Reaction of 2-Methoxytropone (4b) with o-Phenylenediamine (2a). A solution of **4b** (250 mg, 1.84 mmol) and **2a** (240 mg, 2.22 mmol) in EtOH (5 cm³) was heated in a sealed tube for 6 h at 80 °C and then the solution was set aside at room temperature, depositing crystals after several hours. The precipitates were filtered off, giving **13a** (238 mg, 61%, combined with second crop). Compound **10a** (37 mg, 10%) and unreacted **4b** (56 mg, 22%) were isolated by preparative HPLC.

Heating of an ethanolic solution of **13a** in a sealed tube at 120 °C for 6 h gave a quantitative yield of **10a**.

2-(o-Aminophenylamino)tropone (13a): Yellow needles (from EtOH), mp 183–183.5 °C; UV (MeOH) $\lambda_{\max}$ 235, 338, and 401 nm (log ϵ 4.45, 4.00, and 4.10), (MeOH+HCl) 236, 280, 289, 333, 345, 439, 464, and 490 nm (log ϵ 4.22, 4.41, 4.52, 3.95, 3.92, 3.92, 4.04, and 3.90); IR (KBr) 3460, 3320 (NH₂), 3240 (NH), and 1620 cm⁻¹ (C=O); ¹H NMR (CDCl₃) δ =3.75 (2H, br, NH₂), 6.64 (1H, dd, J =10.3 and 1.0 Hz, H-7), 6.75–7.46 (9H, m, ar-H), and 8.33 (1H, br, NH); MS, m/z 212 (M⁺).

Anal. (C₁₃H₁₂N₂O) C, H, N.

6H-Cyclohepta[b]quinoxaline (10a): Pale yellow needles (from CHCl₃); mp 68–69 °C; UV (MeOH) $\lambda_{\max}$ 235, 243, and 342 nm (log ϵ 4.21, 4.21, and 3.94), (MeOH+HCl) 238, 280, 289, 333, 345, 449, 464, and 491 nm (log ϵ 4.21, 4.34, 4.42, 3.92, 3.90, 3.79, 3.91, and 3.79), (MeOH+NaOH) 231, 247, 270, 349, and 392 nm (log ϵ 4.27, 4.26, 4.17, 3.94, and 3.48); ¹H NMR (CD₃CN) δ =3.59 (2H, d, J =5.8 Hz, CH₂), 6.08 (1H, dt, J =10.3 and 5.8 Hz, H-7), 6.28 (1H, dd, J =10.3 and 5.3 Hz, H-8), 6.80 (1H, dd, J =11.7 and 5.3 Hz, H-9), 7.71 (2H, m, H-2,3), 7.28 (1H, d, J =11.7 Hz, H-10) and 8.05 (2H, m, H-1,4); MS, m/z 194 (M⁺).

Anal. (C₁₃H₁₀N₂) C, H, N.

Reaction of 5-Isopropyl-2-methoxytropone (4d) with 2a. Reaction of **4d** (200 mg, 1.12 mmol) with **2a** (145 mg, 1.34 mmol) as described above gave **13b** (153 mg, 54%), **10b** (18 mg, 7%) and unreacted **4d** (54 mg, 27%).

Heating of **13b** (100 mg, 0.39 mmol) as described for **13a** (see above) gave **10b** (73 mg, 79%) and unreacted **13b** (27 mg, 27%).

2-(o-Aminoanilino)-5-isopropyltropone (13b): Yellow needles (from EtOH); mp 155–156 °C; UV (MeOH) $\lambda_{\max}$ 236, 341, and 405 nm (MeOH+HCl) 236, 283, 291, 334, 347, 448, 471, and 500 nm; ¹H NMR (CDCl₃) δ =1.20 (6H, d, J =6.8 Hz, 2CH₃), 2.79 (1H, sept, J =6.8 Hz, CH), 3.77 (2H, br, NH₂), 6.57 (1H, d, J =10.3 Hz, H-7), 6.78–7.28 (7H, m, ar-H), and 8.14 (1H, br, NH); MS, m/z 254 (M⁺).

Anal. (C₁₆H₁₈N₂O) C, H, N.

8-Isopropyl-6H-cyclohepta[b]quinoxaline (10b): Pale yellow oil; UV (MeOH) $\lambda_{\max}$ 213, 247, and 340 nm (MeOH+HCl) 215, 249, 292, 340, and 468 nm; ¹H NMR

(CDCl₃) δ =1.05 (6H, d, J =6.8 Hz, 2CH₃), 2.48 (1H, sept, J =6.8 Hz, CH), 3.51 (2H, d, J =6.3 Hz, CH₂), 5.81 (1H, t, J =6.3 Hz, H-7), 7.72 (1H, d, J =12.2 Hz, H-9), 7.71 (2H, m, H-2,3), 7.80 (1H, d, J =12.2 Hz, H-10), and 8.03 (2H, m, H-1,4); MS, m/z 236 (M⁺).

Anal. (C₁₆H₁₆N₂) C, H, N.

5H-Cyclohepta[b]quinoxalium Salts (9a). A solution of **10a** (100 mg, 0.52 mmol) in EtOH (2 cm³) was treated with various acids (1:2); the mixture was set aside at room temperature, depositing crystals. The precipitates were filtered off, giving **9a** (BF₄⁻ salt, 121 mg, 85%) as dark green needles. BF₄⁻ salt: mp 227.2–229 °C; UV (MeOH) $\lambda_{\max}$ 236, 279sh, 289, 331, 445, 449sh, 464, and 481sh (log ϵ 4.16, 4.37, 4.46, 3.89, 3.84, 3.96, 4.00, and 3.94), (MeOH+NaOH) 231, 246, 347, and 391 (log ϵ 4.24, 4.22, 3.85, and 3.31); ¹H NMR (CD₃CN) δ =5.68 (2H, d, J =11.2 Hz, H-6,10), 6.04 (1H, t, J =9.5 Hz, H-8), 6.14 (2H, m, H-1,4), 6.52 (2H, m, H-2,3), 6.62 (2H, dd, J =11.2 and 9.5 Hz, H-7,9), and 7.95 (2H, br, NH).

Anal. (C₁₃H₁₁N₂BF₄) C, H, N.

ClO₄⁻ salt: mp 227–228.5 °C. CF₃COO⁻ salt: mp 198–199 °C. Br⁻ salt: mp 300 °C. Cl⁻ salt: mp 190–190.5 °C.

8-Isopropyl-5H-cyclohepta[b]quinoxalium Salts (9b). Treatment of **10b** (50 mg, 0.21 mmol) with acid (as described above) gave **9b** (BF₄⁻ salt, 57 mg, 83%) as dark green needles. BF₄⁻ salt: mp 237–238 °C; UV (MeOH) $\lambda_{\max}$ 236, 283, 291, 338, 347, 446, 470, and 500 nm (log ϵ 4.18, 4.35, 4.48, 3.91, 3.83, 3.96, 4.04, and 3.87), (MeOH+NaOH) 245 and 341 nm (log ϵ 4.29 and 3.85); ¹H NMR (CD₃CN) δ =1.10 (6H, d, J =6.8 Hz, 2CH₃), 2.39 (1H, m, J =6.8 Hz, CH), 5.71 (2H, d, J =11.5 Hz, H-6,10), 6.10 (2H, m, H-1,4), 6.48 (2H, m, H-2,3), 6.64 (2H, J =11.5 Hz, H-7,9), and 7.75 (2H, br, NH).

Found: C, 58.97; H, 5.51; N, 8.43%. Calcd for C₁₆H₁₇N₂BF₄: C, 59.29; H, 5.29; N, 8.64%.

ClO₄⁻ salt: mp 289–290 °C.

6,6'-Bi-6H-cyclohepta[b]quinoxaline (16a): Aqueous NaHCO₃ was slowly added to a suspension of **9a** (BF₄⁻ salt, 100 mg, 0.35 mmol) in EtOH (1 cm³); the mixture was allowed to stand overnight exposed to air. The precipitates were filtered off and extracted with CHCl₃. The extracts were combined with the precipitates and purified by preparative HPLC, giving **16a** (57 mg, 84%, RT 32 min) as colorless plates: mp 193.5–194.5 °C (from CHCl₃); UV (MeOH) $\lambda_{\max}$ 215, 233, and 338 nm; ¹H NMR (270 MHz in CDCl₃) δ =4.59 (2H, br, H-6,6'), 6.20 (2H, d, J =10.2 Hz, H-7,7'), 6.43 (2H, dd, J =10.2 and 5.1 Hz, H-8,8'), 7.02 (1H, dd, J =11.7 and 5.1 Hz, H-9,9'), 7.40 (2H, t, J =8.1 Hz, H-3,3' or 2,2'), 7.49 (2H, d, J =8.1 Hz, H-4,4' or 1,1'), 7.53 (2H, t, J =8.1 Hz, H-2,2' or 3,3'), 7.54 (2H, d, J =11.7 Hz, H-10,10'), and 7.96 (2H, d, J =8.1 Hz, H-1,1' or 4,4'); MS, m/z 386 (M⁺, 7), 294 (58), 193 (100), and 192 (30).

Anal. (C₂₆H₁₈N₄) C, H, N.

6,6'-Bicycloheptiden[b]quinoxaline (19): Heating of **16a** of 220 °C in vacuo in a sealed tube gave **10a** and **19** (observed by HPLC). **19**: reddish brown needles, mp 300 °C decomp.; MS m/z 384 (M⁺, 100), 193 (6), and 191 (23); UV (Hexane-MeOH) $\lambda_{\max}$ 217, 249, 349, and 404 nm.

8,8'-Diisopropyl-6,6'-bi-6H-cyclohepta[b]quinoxaline (16b). Treatment of **9b** (BF₄⁻ salt, 50 mg, 0.15 mmol) with alkali (as described above) gave **16b** (27 mg, 74%) as pale yellow needles: mp 134–135 °C; UV (MeOH) $\lambda_{\max}$ 220, 244, and 336 nm; ¹H NMR (CDCl₃) δ =1.08 (6H, d, J =6.8 Hz, 2CH₃), 1.13 (6H, d, J =6.8 Hz, 2CH₃), 2.59 (2H, m, J =6.8 Hz, CH), 4.50 (2H, br, H-6,6'), 5.88 (2H, br, H-7,7'), 7.00 (2H, d,

$J=11.7$ Hz, H-9,9'), 7.39–7.61 (8H), and 7.91–8.01 (2H); MS, m/z 470 (M^+).

Anal. ($C_{32}H_{30}N_4$) C, H, N.

5-Methyl-5*H*-cyclohepta[*b*]quinoxaline (21a). A solution of **4b** (224 mg, 1.65 mmol) and *N*-methyl-*o*-phenylenediamine (**20a**) (251 mg, 2.06 mmol) in EtOH (2 cm³) was heated in a sealed tube for 24 h at 120 °C. After removing the solvent, the residue was taken in a small amount of CHCl₃ and chromatographed on silica-gel thin-layer plates with acetonitrile as the eluant, giving **21a** (237 mg, 69%) as dark green needles along with unreacted **4b** (16 mg, 7%): mp 68 °C; UV (MeOH) λ_{max} 229, 274, 324, 429, 458, 525, 568, 630, and 696 nm ($\log \epsilon$ 4.09, 4.22, 3.87, 3.98, 3.75, 2.62, 2.61, 2.45, and 2.15), (MeOH+HCl) 237, 288, 334, 430, 451, 485, 565, 616, 670, and 752 nm ($\log \epsilon$ 4.17, 4.33, 3.91, 3.79, 3.91, 3.76, 3.01, 2.91, 2.83, and 2.34); ¹H NMR (270 MHz in CD₃CN) $\delta=2.67$ (3H, s, CH₃), 4.47 (1H, d, $J=9.7$ Hz, H-6), 5.22 (1H, dd, $J=10.8$ and 7.6 Hz, H-8), 5.40 (1H, $J=12.3$ Hz, H-10), 5.79 (1H, ddd, $J=12.3$, 7.6, and 1.5 Hz, H-9), 5.84 (1H, ddd, $J=10.8$, 9.7, and 1.5 Hz, H-7), 6.24 (1H, dd, $J=8$ and 1.5 Hz, H-4), 6.48 (1H, dd, $J=8$ and 1.5 Hz, H-6), 6.52 (1H, td, $J=8$ and 1.5 Hz, H-2), and 6.68 (1H, td, $J=8$ and 1.5 Hz, H-3), (250 MHz in CF₃COOD) $\delta=3.02$ (3H, s, CH₃), 5.95 (1H, d, $J=11$ Hz, H-10), 6.08 (1H, d, $J=11$ Hz, H-10), 6.35 (1H, t, $J=9$ Hz, H-8), 6.37 (1H, dd, $J=7.5$ and 1.5 Hz, H-4), 6.51 (1H, dd, $J=8$ and 1.5 Hz, H-1), 6.78 (1H, td, $J=8$, 7.5 and 1.5 Hz, H-3), 6.88 (1H, ddd, $J=11$, 9 and 1.5 Hz, H-9), 6.88 (1H, td, $J=8$ and 1.5 Hz, H-2) and 7.01 (1H, ddd, $J=11$, 9, and 1.5 Hz, H-7); MS, m/z 208 (M^+).

Anal. ($C_{14}H_{12}N_2$) C, H, N.

8-Isopropyl-5-methyl-5*H*-cyclohepta[*b*]quinoxaline (21b). The reaction of **4c** and **20a** was conducted in a manner similar to that described above for **21a**, giving **21b** in 51% yield: Dark green oil; mp 200 °C (picrate); UV (MeOH) λ_{max} 228, 260, 282, 324, 432, 525, 568, 628, and 686 nm ($\log \epsilon$ 4.19, 4.18, 4.27, 3.29, 3.99, 2.88, 2.81, 2.62, and 2.30), (MeOH+HCl) 237, 299, 332, 428, 446, 488, 564, 616, 672, and 760 nm ($\log \epsilon$ 4.24, 4.60, 3.97, 3.88, 4.00, 3.83, 3.01, 2.99, 2.84, and 2.23); ¹H NMR (100 MHz in CDCl₃) $\delta=0.98$ (6H, d, $J=6.6$ Hz, 2CH₃), 2.09 (1H, sept, $J=6.6$ Hz, CH), 2.70 (3H, s, N-CH₃), 4.41 (1H, d, $J=9.8$ Hz, H-6), 5.47 (1H, d, $J=12.5$ Hz, H-9), 5.74 (1H, d, $J=9.8$ Hz, H-7), 6.01 (1H, d, $J=12.5$ Hz, H-10), 6.12 (1H, d, $J=7.3$ Hz, H-4), 6.61 (3H, m, H-1,2,3), (CF₃COOD) $\delta=1.15$ (6H, d, $J=7.1$ Hz, 2CH₃), 2.51 (1H, sept, $J=7.1$ Hz, CH), 2.98 (3H, s, N-CH₃), 5.93 (1H, d, $J=12$ Hz, H-6), 6.07 (1H, d, $J=12$ Hz, H-10), 6.30 (1H, d, $J=7$ Hz, H-4), 6.41 (1H, d, $J=7$ Hz, H-1), 6.70 (2H, m, H-2,3), 6.88 (1H, d, $J=12$ Hz, H-9 or 7) and 6.98 (1H, d, $J=12$ Hz, H-7 or 9); MS, m/z 250 (M^+).

Anal. ($C_{17}H_{18}N_2$) C, H, N.

5,11-Dimethyl-5*H*-cyclohepta[*b*]quinoxalinium Salts (23). (a) Conc'd HCl (100 mg) was added to a solution of **4a** (300 mg, 2.14 mmol) and *N,N'*-dimethyl-*o*-phenylenediamine **20b** (436 mg, 3.21 mmol) in EtOH (2 cm³); the mixture was heated in a sealed tube for 20 h at 120 °C. After cooling, the precipitates were collected, giving **23** (481 mg, 87% with the second crop). (b) The reaction of **4b** (120 mg, 0.88 mmol) with **20b** (180 mg, 1.32 mmol) and 42% HBF₄ as above gave the BF₄⁻ salt (106 mg, 39%). Cl⁻ salt: Dark green needles; mp 230 °C (from EtOH); UV (MeOH) λ_{max} 238, 287, 328, 440, 580, 620, and 630 nm. ($\log \epsilon$ 4.18, 4.23, 3.84, 3.81, 3.07, 3.05, and 2.56); ¹H NMR (270 MHz in CD₃CN) $\delta=3.10$ (6H, s, 2CH₃), 6.25 (2H, d, $J=11$ Hz, H-6, 10), 6.57 (1H, t, $J=9.5$ Hz, H-8), 6.71 (2H, m, H-1, 4), 6.95 (2H, m, H-2, 3), and 7.24 (2H, dd,

$J=11.3$ and 9.5 Hz, H-7,9).

Anal. ($C_{15}H_{16}N_2Cl$) C, H, N.

BF₄⁻ salt: Dark green needles; mp 223 °C

Reaction of 23 with NaOH. (a) Aqueous NaOH (1 g/3 cm³ of H₂O) was added to a green solution of **23** (150 mg, 0.58 mmol) in MeOH (150 cm³); the solution turned to colorless. After removing the solvent, the residue was extracted with CHCl₃. The combined extracts were concentrated and chromatographed on a silica-gel column with 10:1 benzene-MeOH as the eluant, giving **29** (124 mg, 89%). (b) Aqueous NaOH (80 mg/ H₂O, 0.5 cm³) was added to a solution of **23** (100 mg, 0.39 mmol) in MeOH (100 cm³) and the solution was set aside overnight at room temperature; it slowly became reddish brown. After removing the solvent, the residue was chromatographed on silica-gel thin-layer plates with 10:1 benzene-MeOH as the eluant, giving **30** (5 mg, 6.5%) besides **29** (11%) and many products.

***N*-Methyl-*N*-[*o*-(methylamino)phenyl]benzamide (29):** Colorless needles (from MeOH), mp 140 °C; MS, m/z 240 (M^+); UV (MeOH) λ_{max} 238 and 301 nm ($\log \epsilon$ 4.19 and 3.57), (MeOH+HCl) 233, 271, and 278 nm ($\log \epsilon$ 4.15, 4.08, and 4.14); IR (KBr) 3360 (NH) and 1630 cm⁻¹ (CO); ¹H NMR (270 MHz in CDCl₃) $\delta=2.92$ (3H, d, $J=5.5$ Hz, CH₃), 3.29 (3H, s, CH₃), 4.19 (1H, q, $J=5.5$ Hz, NH), 6.46 (1H, t, $J=7.7$ Hz), 6.61 (1H, d, $J=8.2$ Hz), 6.71 (1H, d, $J=7.7$ Hz), 7.12 (3H, m), 7.20 (1H, d, $J=7.1$ Hz) and 7.29 (2H, dd, $J=7.7$ and 7.1 Hz); MS, m/z 240 (M^+ , 41), 163 (12), 135 (31), 120 (28), 119 (78), 106 (9), 105 (42), 91 (9), and 77 (100).

Anal. ($C_{15}H_{16}N_2O$) C, H, N.

5,10-Dihydro-5,10-dimethyl-2-phenazinecarbaldehyde (30): Reddish orange crystals; mp 83 °C (lit.¹²) red plates, mp 185 °F; UV (MeOH) λ_{max} 237, 288, 351, and 432 nm ($\log \epsilon$ 4.38, 4.37, 3.65, and 3.37), (MeOH+HCl) 241, 260, 290, 348, and 442 nm ($\log \epsilon$ 4.36, 4.16, 4.25, 3.68, and 3.69); ¹H NMR (270 MHz in C₆D₆) $\delta=2.28$ (3H, s, CH₃), 2.30 (3H, s, CH₃), 5.82 (1H, d, $J=7.7$ Hz, H-4), 5.99 (2H, m, H-6,9), 6.64 (2H, m, H-7,8), 6.81 (1H, d, $J=1.7$ Hz, H-1), and 6.89 (1H, dd, $J=7.7$ and 1.7 Hz, H-3); MS, m/z 238 (M^+ , 77), 238 (86), 195 (100), and 180 (48).

Found: m/z 238.1113. Calcd for C₁₅H₁₄N₂O: M, 238.1105.

5,11-Dihydro-8,11-dimethyl-6*H*-cyclohepta[*b*]quinoxaline-5,6-sultone (24b). A solution of **21a** (100 mg, 0.96 mmol) and methyl fluorosulfate (200 mg, 1.75 mmol) in dichloromethane (0.5 cm³) was shaken in a sealed flask for 40 h at room temperature. After removing the solvent and excess sulfate in vacuo, the residue was diluted with aqueous NaHCO₃ and then extracted with CHCl₃. The extracts were combined and concentrated in vacuo. The residue was chromatographed on silica-gel thin-layer plates with 10:1 benzene-MeOH as the eluant, giving **24** (178 mg, 61%) as green needles: mp 127–128.5 °C (from CHCl₃); UV (MeOH) λ_{max} 268, 276, 328, 443, 464, 616, 676, and 680 nm ($\log \epsilon$ 4.43, 4.38, 4.09, 4.27, 4.22, 3.20, 3.08, 2.72) (MeOH+NaOH) 230, 250, 280, and 354 nm. (MeOH+HCl) 240, 284, 334, 432, 460, 490, 564, 622, and 684 nm ($\log \epsilon$ 4.31, 4.45, 4.21, 4.04, 4.29, 4.30, 3.07, 3.01, 2.80), (hexane) 265, 322, and 434 nm; IR (KBr) 1160, 1340 cm⁻¹ (–SO₂–); ¹H NMR (270 MHz in C₆D₆) $\delta=1.63$ (3H, s, CH₃), 3.29 (3H, s, N-CH₃), 3.33 (1H, d, $J=10.2$ Hz, H-6), 5.49 (1H, d, $J=12.8$ Hz, H-10), 5.61 (1H, dt, $J=9.5$ and 3.3 Hz, H-1), 5.98 (1H, dd, $J=12.8$ and 2.2 Hz, H-9), 6.44 (1H, dd, $J=10.2$ and 2.2 Hz, H-7), 6.44 (2H, m, H-2,3), and 6.88 (1H, dt, $J=9.5$ and 3.3 Hz, H-4), (270 MHz in CD₃CN) $\delta=2.86$ (3H, s, CH₃), 3.74 (3H, s, N-CH₃), 4.47 (1H, d, $J=11.0$

Hz, H-6), 5.38 (1H, d, $J=13.2$ Hz, H-10), 5.90 (1H, dd, $J=13.2$ and 2.2 Hz, H-9), 6.51 (1H, dd, $J=11.0$ and 2.2 Hz, H-7), 6.54 (1H, d, $J=6.6$ Hz, H-1), 6.69 (1H, dd, $J=6.5$ and 1.5 Hz, H-4), 6.74 (1H, td, $J=6.5$ and 1.5 Hz, H-3), 6.86 (1H, td, $J=6.5$ and 1.5 Hz, H-2), (270 MHz in $\text{CD}_3\text{CN}+\text{CF}_3\text{COOD}$) $\delta=2.99$ (3H, s, CH_3), 3.81 (3H, s, CH_3), 5.69 (1H, d, $J=11.7$ Hz, H-10), 5.83 (1H, d, $J=11.7$ Hz, H-6), 6.56 (1H, dd, $J=7.5$ and 1.5 Hz, H-4), 6.71 (1H, dd, $J=7.5$ and 1.5 Hz, H-1), 6.87 (1H, td, $J=7.5$ and 1.5 Hz, H-2), 6.95 (1H, td, $J=7.5$ and 1.5 Hz, H-3), 7.05 (1H, dd, $J=11.7$ and 2.2 Hz, H-9) and 7.20 (1H, dd, $J=11.7$ and 2.2 Hz, H-7); MS, m/z 302 (M^+ , 100), 287 (13), 223 (13), 208 (14), 207 (38), 206 (11), 205 (12), 193 (13), 192 (23), 191 (17), and 182 (31).

Found: m/z 302.0679. Calcd for $\text{C}_{15}\text{H}_{14}\text{N}_2\text{O}_3\text{S}$: M, 302.0724.

Oxidation of 10a with H_2O_2 : To a solution of **10a** (20 mg) in acetic acid (2 cm^3) was added 28% H_2O_2 (100 mg), and the mixture was set aside for 24 h at room temperature. Each product was separated and identified by means of HPLC, giving **16a** (80%), **E** and **F** (7%), and **37**¹³ (5%). The yields were based on the peak areas.

Oxidation of 21a with H_2O_2 : Compound **21a** (50 mg) was treated with 28% H_2O_2 (0.1 cm^3) in methanol (0.5 cm^3) at 60 °C for 70 h. Many product spots were seen on TLC, and **39** was separated (10% yield) by using preparative TLC with benzene–MeOH (10 : 1) as eluant.

10-Methyl-2(10H)-phenazinone (39):¹⁴ Red solid; UV (MeOH) λ_{max} 229, 276sh, 284, 355, 512, and 550sh nm ($\log \epsilon$ 4.69, 4.57, 4.60, 3.86, 3.83, and 3.70); ^1H NMR (270 MHz in CDCl_3) $\delta=7.02$ (1H, s, H-1), 7.35 (1H, d, $J=9$ Hz, H-3), 7.64 (1H, t, $J=8$ Hz, H-6), 7.80 (1H, d, $J=8$ Hz, H-8), 7.85 (1H, d, $J=9$ Hz, H-4), 7.89 (1H, t, $J=8$ Hz, H-7), 8.19 (1H, d, $J=8$ Hz, H-6); MS, m/z 210 (M^+ , 74), 182 (100), and 167 (29).

Found: m/z 210.0803. Calcd for $\text{C}_{13}\text{H}_{10}\text{N}_2\text{O}$: M, 210.0793.

We wish to thank Drs. Masafumi Yasunami and Kazuko Takahashi (Tohoku Univ.) and Professor Hiroshi Yamamoto (Okayama Univ.) for their helpful advice, and Mr. Nobuyuki Yoshida (Tokyo Research Laboratories, Kao Corp.) for his help in the early stages of this work.

References

- 1) Presented at the 43rd National Meeting of the Chemical Society of Japan, Tokyo, April 1981, Abstr., No. 1H41; at the 47th Meeting, Tokyo, April 1983, Abstr., No. 4F34; at the 50th Meeting, Tokyo, April 1985, Abstr., No. 1T25.
- 2) T. Nozoe, *Pure Appl. Chem.*, **54**, 975 (1982); T. Nozoe, *Chemistry* (Chinese Chem. Soc. Taiwan), **41**, A43 (1983).
- 3) T. Nozoe, M. Sato, and T. Matsuda, *Sci. Rep. Tohoku Univ.*, First Series, **37**, 407 (1953).
- 4) T. Nozoe, T. Kitahara, K. Takase, and M. Sasaki, *Proc. Jpn. Acad.*, **32**, 349 (1956). Compound **6a** was also formed from the reaction of 1,2-cycloheptanedione and **2a**, and **7a** was obtained by the reduction of **6a**.
- 5) T. Fukunaga, presented at the 23rd IUPAC Congress, Boston, 1971, Abstr., p. 103; also private communication.
- 6) T. Nozoe, H. Okai, and T. Someya, *Bull. Chem. Soc. Jpn.*, **51**, 2185 (1978); T. Nozoe and T. Someya, *ibid.*, **51**, 3316 (1978); T. Nozoe, T. Someya, and H. Okai, *ibid.*, **56**, 2756 (1983).
- 7) T. Nozoe, T. Asao, and K. Takahashi, *Bull. Chem. Soc. Jpn.*, **34**, 146 (1961); **39**, 1980 (1966).
- 8) K. Shindo, S. Ishikawa, and T. Nozoe, *Bull. Chem. Soc. Jpn.*, **58**, 165 (1985).
- 9) Presented at the 50th National Meeting of the Chemical Society of Japan, Tokyo, April 1985, Abstr., No. 1T26.
- 10) A little later, Mukai et al also obtained the same compound (as iodide salt) by methylation of **21a** with methyl iodide: Y. Yamashita, K. Hagiya, Y. Nishizawa, and T. Mukai, presented at the 50th National Meeting of the Chemical Society of Japan, Tokyo, April 1985, Abstr., No. 3T35; at the 18th Japanese Symposium on the Chemistry of Nonbenzenoid Aromatic Compounds, Toyama, Abstr., p. 107 (1985). See also Y. Yamashita, K. Hagiya, G. Saito, and T. Mukai, *Bull. Chem. Soc. Jpn.*, **61**, 271 (1988).
- 11) W. Brasen, H. Holmquist, and R. Benson, *J. Am. Chem. Soc.*, **83**, 3125 (1961).
- 12) M. G. Khristiansen, A. Ya. Il'cheenko, Yu. S. Rozum, *Dopov. Akad. Nauk Ukr. RSR, Ser. B*, **32**, 829 (1970).
- 13) M. Hirama, A. Kawamata, and S. Itô, *Chem. Lett.*, **1979**, 855.
- 14) F. Kehrman and F. Cherpillod, *Helv. Chim. Acta*, **7**, 973 (1924).
- 15) A. R. Katritzky and C. W. Rees, "Comprehensive Heterocyclic Chemistry," ed by M. Sainsbury, Pergamon Press, Oxford (1984), Vol. 3, p. 1010.
- 16) A. Albert, "Heterocyclic Chemistry," Athlone Press London, 1968.
- 17) K. Shindo, K. Kurihara, S. Ishikawa, and T. Nozoe, to be published.